Article
Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas.
The Journal of pathology - 1 Nov 2011
Boult Jessica Kr, Walker-Samuel Simon, Jamin Yann, Leiper James M, Whitley Guy St J, Robinson Simon P
Abstract excerpt
Dimethylarginine dimethylaminohydrolase (DDAH) metabolizes the endogenous inhibitor of nitric oxide synthesis, asymmetric dimethylarginine (ADMA). Constitutive over-expression of DDAH1, the isoform primarily associated with neuronal nitric oxide synthase (nNOS) results in increased tumour growth and vascularization, and elevated VEGF secretion. To address whether DDAH1-mediated tumour growth is reliant upon the...
Topics
Join the communities discussing this publication.